Prostate Cancer

To properly identify and treat patients with prostate cancer, physicians must have an in-depth understanding of the natural history and diagnostic, staging, and treatment options. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support recommendations. Several variables must be considered in tailoring prostate cancer therapy to each individual patient. These guidelines provide a framework on which to base treatment decisions. Important changes to the guidelines since last publication include the introduction of Principles of Life Expectancy Estimation table and changes in recommendations for both hormone and chemotherapy. For the most recent version of the guidelines, please visit NCCN.org

Download Full-text

Prostate Cancer Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2004.0021 ◽

2004 ◽

Vol 2 (3) ◽

pp. 224 ◽

Cited By ~ 20

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Natural History ◽

Radiation Oncology ◽

Medical Oncology ◽

Public Awareness ◽

Treatment Options ◽

Death Rates ◽

Prevalent Disease ◽

Recent Version

Although the incidence of prostate cancer has been increasing (1.4% annually from 1995 to 1999), the age-adjusted death rates from prostate cancer have begun to decline (-4.3% annually from 1994 to 1999), and researchers expect prostate cancer to account for only 28,900 deaths in 2003. This suggests that unless prostate cancer is becoming biologically less aggressive, increased public awareness with earlier detection and treatment of prostate cancer has begun to make an impact on this prevalent disease. To properly identify and manage patients with prostate cancer or any malignancy, physicians must have an in-depth understanding of the natural history and treatment options. To this end, an NCCN panel of leading experts from the fields of urology, radiation oncology, and medical oncology at member institutions was appointed to develop guidelines for the treatment of prostate cancer. For the most recent version of the guidelines, please visit NCCN.org

Download Full-text

New Developments in Prostate Cancer Therapy

American Society of Clinical Oncology Educational Book ◽

10.14694/edbook_am.2012.32.84 ◽

2012 ◽

pp. 309-313

Author(s):

Madhuri Bajaj ◽

Elisabeth I. Heath

Keyword(s):

Prostate Cancer ◽

Cancer Therapy ◽

Cancer Progression ◽

Treatment Options ◽

Malignant Neoplasm ◽

The United States ◽

Growth Factor Signaling ◽

Incurable Disease ◽

Prostate Cancer Therapy ◽

Castrate Resistant

Overview: Prostate cancer is the most common nonskin malignant neoplasm in men worldwide. In the United States, 241,740 new diagnoses of prostate cancer and 28,170 prostate cancer deaths have been estimated for 2012, representing 28% of new cancer cases and 10% of male cancer deaths. 1 Although metastatic prostate cancer remains an incurable disease, substantial advances have been made in therapeutic options available for men in the past several years. Development of novel agents that modulate the androgen receptor pathway, growth factor signaling pathways, and immune function and bone targeting pathways has been the focus of therapeutic strategies because of its significance in the biology of prostate cancer progression. Several of the agents have gained U.S. Food and Drug Administration (FDA) approval, whereas many are in late-stage clinical trials. With the growth of available treatment options, a major challenge as we move forward will be to determine the best sequence and/or combination of therapy that will result in maximum clinical efficacy with minimum toxicity. Highlighted in this publication are several of the exciting advances in prostate cancer therapy for patients with metastatic, castrate-resistant prostate cancer.

Download Full-text